3SBio Inc. (HKG:1530)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
12.96
-0.10 (-0.77%)
Apr 2, 2025, 4:08 PM HKT
116.72%
Market Cap 30.52B
Revenue (ttm) 9.69B
Net Income (ttm) 2.22B
Shares Out 2.36B
EPS (ttm) 0.90
PE Ratio 14.33
Forward PE 11.76
Dividend 0.25 (1.91%)
Ex-Dividend Date Jul 21, 2025
Volume 48,115,487
Average Volume 58,288,148
Open 13.06
Previous Close 13.06
Day's Range 12.66 - 13.44
52-Week Range 5.47 - 13.48
Beta 0.64
RSI 78.30
Earnings Date Mar 21, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 5,577
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1530
Full Company Profile

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.